Discussions tagged “clinicaltrials”

The A-BRAVE trial, has shown that while 1 year of avelumab immunotherapy after standard treatment didn’t improve disease-free survival, it did significantly extend overall survival in high-risk early Triple-negative breast cancer (TNBC) patients. This is a significant finding as TNBC is notoriously aggressive and difficult to treat. What's everyone's take on this? Does this change the standard of care for TNBC or will this be limited to high-risk patients? Any insights on how this might impact future research or treatment options?